Interleukin-1 augments salt retention in angiotensin II-induced hypertension via nitric oxide-dependent regulation of the NKCC2 sodium co-transporter

• Published in: Cell metabolism Vol. 23; no. 2; pp. 360 - 368
• Main Authors: Zhang, Jiandong, Rudemiller, Nathan P., Patel, Mehul B., Karlovich, Norah S., Wu, Min, McDonough, Alicia A., Griffiths, Robert, Sparks, Matthew A., Jeffs, Alexander D., Crowley, Steven D.
• Format: Journal Article
• Language: English
• Published: 17-12-2015
• ISSN: 1550-4131; 1932-7420
• DOI: 10.1016/j.cmet.2015.11.013

Hypertension is among the most prevalent and catastrophic chronic diseases worldwide. While the efficacy of renin angiotensin system (RAS) blockade in lowering blood pressure illustrates that the RAS is broadly activated in human hypertension, the frequent failure of RAS inhibition to prevent or reverse hypertensive organ damage highlights the need for novel therapies to combat RAS-dependent hypertension. We previously discovered elevated levels of the macrophage cytokine IL-1 in the kidney in a murine model of RAS-mediated hypertension. Here we report that IL-1 receptor (IL-1R1) deficiency or blockade limits blood pressure elevation in this model by mitigating sodium reabsorption via the NKCC2 co-transporter in the nephron. In this setting, IL-1R1 activation prevents intra-renal myeloid cells from maturing into Ly6C
+
Ly6G
−
macrophages that elaborate nitric oxide, a natriuretic hormone that suppresses NKCC2 activity. By revealing how the innate immune system regulates tubular sodium transport, these experiments should lead to new immunomodulatory anti-hypertensive therapies.